Moderna (MRNA) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Moderna (MRNA) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 618.7% versus a gain of 4.7%. Over five years, NBIX leads with a +37.2% price change compared with -39.4% for MRNA. Moderna is the larger company by market cap ($78.34 billion vs $14.28 billion), about 5.5 times the size, while Neurocrine Biosciences is growing revenue faster (+21.4% vs -39.9%).
Neurocrine Biosciences converts more of its revenue into profit, with a net margin of 16.7% versus -145.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRNA | NBIX |
|---|---|---|
| Share price | $196.24 | $140.44 |
| Market cap | $78.34B | $14.28B |
| 1-day change | -0.12% | -2.11% |
| YTD return | +566.26% | +1.16% |
| 1-year return | +618.65% | +4.72% |
| 5-year return | -39.40% | +37.24% |
| P/E ratio (TTM) | — | 20.59 |
| Forward P/E | — | 11.82 |
| EPS (TTM) | $-7.98 | $6.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.94B | $2.86B |
| Revenue growth (YoY) | -39.93% | +21.45% |
| Net income (latest FY) | $-2.82B | $478.60M |
| Gross margin | 55.35% | 98.18% |
| Operating margin | -158.13% | 21.64% |
| Net margin | -145.16% | 16.73% |
| 52-week high | $212.22 | $186.12 |
| 52-week low | $22.28 | $122.14 |
| Distance from 52-week high | -7.53% | -24.54% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -38.34% | +47.60% |
| Average volume | 17.44M | 1.30M |
| Shares outstanding | 399.24M | 101.65M |
| Employees | 4,700 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Moderna is about 5.5 times larger than Neurocrine Biosciences by market value ($78.34B vs $14.28B).
- MRNA has outperformed NBIX by 613.9 percentage points over the past year.
- Neurocrine Biosciences is more profitable, keeping 16.7 cents of every revenue dollar as net income versus -145.2 cents for Moderna.
- Neurocrine Biosciences grew revenue faster in its latest fiscal year (+21.45% vs -39.93%).
About Moderna
MRNA stock →Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4,700 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
MRNA vs NBIX FAQ
Which is bigger, Moderna or Neurocrine Biosciences?
Moderna (MRNA) is larger, with a market capitalization of $78.34B compared with $14.28B for Neurocrine Biosciences (NBIX).
Which stock has performed better over the past year, MRNA or NBIX?
MRNA returned +618.65% over the past 12 months, compared with +4.72% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Are Moderna and Neurocrine Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.